India Globalization Capital Inc. (NYSE American: I
Post# of 436
(Total Views: 247)
Posted On: 03/07/2023 3:43:58 PM
India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase
- Government showing strong support for bills aimed at treating Alzheimer’s disease
- IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2
- Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease”
Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://nnw.fm/YNK6P ). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a company pursuing effective treatment for Alzheimer patients suffering with agitation and other neuropsychiatric symptoms.
“The Alzheimer’s Association and the Alzheimer’s Impact Movement (“AIM”) are proud to support the bipartisan introduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act,” reported a recent Alzheimer’s Association article. “Reintroduced [on Jan. 31, 2023] in Congress, the NAPA Reauthorization Act would extend the National Alzheimer’s Project Act, and the Alzheimer’s Accountability and Investment Act will ensure Congress continues to hear directly from scientists on what resources are needed to prevent and effectively treat Alzheimer’s disease.”
According to the article, the act was first introduced in the 117th Congress, which convened in January 2021. At the time, AIM advocates worked to build bipartisan support for both the NAPA act, eventually landing 65 cosponsors in the House and 27 in the Senate, and the Alzheimer’s Accountability and Investment Act, with 45 cosponsors in the House and 24 in the Senate. AIM representatives noted that they are working to expand that bipartisan progress with the 118th Congress.
“On behalf of the Alzheimer’s community, we thank the Senate and House sponsors for reintroducing these important bipartisan bills to continue the progress we have made in the fight against Alzheimer’s and all other dementia,” said Robert Egge, Alzheimer’s Association chief public policy officer and AIM executive director. “These bills reaffirm our nation’s commitment by helping to secure federal investments in Alzheimer’s research and improve access to better quality care and support services for individuals living with Alzheimer’s and their caregivers. We look forward to working together to pass these bipartisan bills and help improve the lives of those impacted by Alzheimer’s and other dementia throughout the nation.”
AIM isn’t the only organization focused on helping those dealing with Alzheimer’s. IGC’s leading drug candidate, IGC-AD1, recently completed phase 1 of a safety and tolerability trial and entered phase 2 trials. The study, which is the first in humans of a natural low-doses tetrahydrocannabinol (“THC”) compound plus another molecule, is designed to evaluate IGC-AD1 as a treatment for agitation in patients with Alzheimer’s dementia. In addition, IGC has a second drug candidate: TGR-63. An enzyme inhibitor, TGR-63 has shown the potential to reduce neurotoxicity in Alzheimer’s cell lines.
Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.
“We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials,” said IGC CEO Ram Mukunda (https://nnw.fm/Ue6zf ). “Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as APOE e4 a gene that increases the risk of developing Alzheimer’s.
“This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in treating a disease that has a global impact like Alzheimer’s,” he continued. “Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s disease.”
IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.
For more information, visit the company’s website at www.IGCPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://nnw.fm/IGC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Government showing strong support for bills aimed at treating Alzheimer’s disease
- IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2
- Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease”
Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://nnw.fm/YNK6P ). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a company pursuing effective treatment for Alzheimer patients suffering with agitation and other neuropsychiatric symptoms.
“The Alzheimer’s Association and the Alzheimer’s Impact Movement (“AIM”) are proud to support the bipartisan introduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act,” reported a recent Alzheimer’s Association article. “Reintroduced [on Jan. 31, 2023] in Congress, the NAPA Reauthorization Act would extend the National Alzheimer’s Project Act, and the Alzheimer’s Accountability and Investment Act will ensure Congress continues to hear directly from scientists on what resources are needed to prevent and effectively treat Alzheimer’s disease.”
According to the article, the act was first introduced in the 117th Congress, which convened in January 2021. At the time, AIM advocates worked to build bipartisan support for both the NAPA act, eventually landing 65 cosponsors in the House and 27 in the Senate, and the Alzheimer’s Accountability and Investment Act, with 45 cosponsors in the House and 24 in the Senate. AIM representatives noted that they are working to expand that bipartisan progress with the 118th Congress.
“On behalf of the Alzheimer’s community, we thank the Senate and House sponsors for reintroducing these important bipartisan bills to continue the progress we have made in the fight against Alzheimer’s and all other dementia,” said Robert Egge, Alzheimer’s Association chief public policy officer and AIM executive director. “These bills reaffirm our nation’s commitment by helping to secure federal investments in Alzheimer’s research and improve access to better quality care and support services for individuals living with Alzheimer’s and their caregivers. We look forward to working together to pass these bipartisan bills and help improve the lives of those impacted by Alzheimer’s and other dementia throughout the nation.”
AIM isn’t the only organization focused on helping those dealing with Alzheimer’s. IGC’s leading drug candidate, IGC-AD1, recently completed phase 1 of a safety and tolerability trial and entered phase 2 trials. The study, which is the first in humans of a natural low-doses tetrahydrocannabinol (“THC”) compound plus another molecule, is designed to evaluate IGC-AD1 as a treatment for agitation in patients with Alzheimer’s dementia. In addition, IGC has a second drug candidate: TGR-63. An enzyme inhibitor, TGR-63 has shown the potential to reduce neurotoxicity in Alzheimer’s cell lines.
Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.
“We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials,” said IGC CEO Ram Mukunda (https://nnw.fm/Ue6zf ). “Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as APOE e4 a gene that increases the risk of developing Alzheimer’s.
“This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in treating a disease that has a global impact like Alzheimer’s,” he continued. “Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s disease.”
IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.
For more information, visit the company’s website at www.IGCPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://nnw.fm/IGC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)